Fmr LLC Has $716,000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

FMR LLC boosted its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 292.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 221,001 shares of the company's stock after buying an additional 164,622 shares during the quarter. FMR LLC owned 0.32% of Amylyx Pharmaceuticals worth $716,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its position in Amylyx Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company's stock valued at $42,000 after buying an additional 5,104 shares during the period. Algert Global LLC bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $47,000. CWM LLC lifted its holdings in Amylyx Pharmaceuticals by 104.2% in the 2nd quarter. CWM LLC now owns 28,643 shares of the company's stock worth $54,000 after purchasing an additional 14,613 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Amylyx Pharmaceuticals by 88.4% during the second quarter. Allspring Global Investments Holdings LLC now owns 28,785 shares of the company's stock worth $55,000 after purchasing an additional 13,509 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Amylyx Pharmaceuticals by 113.6% in the second quarter. SG Americas Securities LLC now owns 55,836 shares of the company's stock worth $106,000 after purchasing an additional 29,697 shares during the period. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX opened at $4.28 on Wednesday. The firm has a 50 day simple moving average of $5.06 and a two-hundred day simple moving average of $3.20. The company has a market cap of $293.39 million, a P/E ratio of -1.12 and a beta of -0.68. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $19.95.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 11,442 shares of the business's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total transaction of $36,614.40. Following the sale, the insider now owns 143,801 shares of the company's stock, valued at approximately $460,163.20. The trade was a 7.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Justin B. Klee sold 18,589 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $59,484.80. Following the completion of the transaction, the chief executive officer now owns 3,120,569 shares of the company's stock, valued at $9,985,820.80. The trade was a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on AMLX shares. HC Wainwright restated a "buy" rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Bank of America raised Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the company from $4.20 to $10.00 in a research note on Wednesday, October 23rd. Leerink Partners set a $4.00 price objective on shares of Amylyx Pharmaceuticals and gave the stock a "market perform" rating in a report on Friday, October 18th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $3.00 to $11.00 in a research note on Monday, November 18th. Finally, Baird R W raised Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.